HRP20090127T3 - Carboxamide derivatives as muscarinic receptor antagonists - Google Patents

Carboxamide derivatives as muscarinic receptor antagonists

Info

Publication number
HRP20090127T3
HRP20090127T3 HR20090127T HRP20090127T HRP20090127T3 HR P20090127 T3 HRP20090127 T3 HR P20090127T3 HR 20090127 T HR20090127 T HR 20090127T HR P20090127 T HRP20090127 T HR P20090127T HR P20090127 T3 HRP20090127 T3 HR P20090127T3
Authority
HR
Croatia
Prior art keywords
alkyl
independently selected
halo
optionally substituted
receptor antagonists
Prior art date
Application number
HR20090127T
Other languages
English (en)
Croatian (hr)
Inventor
Alan Glossop Paul
John Mantell Simon
Sinclair Strang Ross
Anne Louise Watson Christine
Wood Anthony
Original Assignee
Pfizer Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Limited filed Critical Pfizer Limited
Publication of HRP20090127T3 publication Critical patent/HRP20090127T3/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20090127T 2005-09-21 2009-03-02 Carboxamide derivatives as muscarinic receptor antagonists HRP20090127T3 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71946705P 2005-09-21 2005-09-21
US71946805P 2005-09-21 2005-09-21
US71947705P 2005-09-21 2005-09-21
PCT/IB2006/002727 WO2007034325A1 (en) 2005-09-21 2006-09-01 Carboxamide derivatives as muscarinic receptor antagonists

Publications (1)

Publication Number Publication Date
HRP20090127T3 true HRP20090127T3 (en) 2009-06-30

Family

ID=37698323

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20090127T HRP20090127T3 (en) 2005-09-21 2009-03-02 Carboxamide derivatives as muscarinic receptor antagonists

Country Status (43)

Country Link
US (3) US7772223B2 (nl)
EP (1) EP1928821B1 (nl)
JP (1) JP4221447B1 (nl)
KR (1) KR100976909B1 (nl)
CN (1) CN101268046B (nl)
AP (1) AP1983A (nl)
AR (1) AR055171A1 (nl)
AT (1) ATE420069T1 (nl)
AU (1) AU2006293618B9 (nl)
BR (1) BRPI0616111B8 (nl)
CA (1) CA2623332C (nl)
CR (2) CR9814A (nl)
CU (1) CU20100115A7 (nl)
CY (1) CY1108880T1 (nl)
DE (1) DE602006004768D1 (nl)
DK (1) DK1928821T3 (nl)
DO (1) DOP2006000202A (nl)
EA (1) EA013083B1 (nl)
EC (1) ECSP088265A (nl)
ES (1) ES2318794T3 (nl)
GE (1) GEP20104880B (nl)
GT (1) GT200600422A (nl)
HK (1) HK1117163A1 (nl)
HN (1) HN2006032615A (nl)
HR (1) HRP20090127T3 (nl)
IL (1) IL189453A (nl)
MA (1) MA29839B1 (nl)
ME (1) ME01106B (nl)
MX (1) MX2008002805A (nl)
MY (1) MY143581A (nl)
NL (1) NL2000241C2 (nl)
NO (1) NO340975B1 (nl)
NZ (1) NZ566023A (nl)
PE (1) PE20070460A1 (nl)
PL (1) PL1928821T3 (nl)
PT (1) PT1928821E (nl)
RS (2) RS51680B (nl)
SI (1) SI1928821T1 (nl)
TN (1) TNSN08137A1 (nl)
TW (1) TWI322143B (nl)
UY (1) UY29798A1 (nl)
WO (1) WO2007034325A1 (nl)
ZA (1) ZA200801432B (nl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008002246A1 (en) * 2006-06-28 2008-01-03 Astrazeneca Ab A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient.
WO2008035157A1 (en) * 2006-09-22 2008-03-27 Pfizer Limited Azetidine derivatives as muscarinic receptor antagonists
DK2125714T3 (da) * 2007-03-16 2011-07-25 Pfizer Ltd Hydrochloridsalt af 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamid
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドPfizer Limited 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
CA2805117A1 (en) * 2010-08-26 2012-03-01 Albemarle Corporation Processes for producing 1-bromo-2-(cyclopropyl methoxy)-5-fluoro-4-methoxybenzene
CN103242214B (zh) * 2013-05-02 2016-04-06 陕西步长高新制药有限公司 一种吲哚衍生物及其制备方法
KR101538846B1 (ko) * 2013-07-30 2015-07-22 동아에스티 주식회사 신규한 바이페닐 유도체 및 그의 제조방법
WO2018167804A1 (en) * 2017-03-15 2018-09-20 Mylan Laboratories Limited Novel polymorphs of (5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide hydrochloride
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CA3077499C (en) 2017-10-05 2021-09-21 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd
JP2022503740A (ja) 2018-09-19 2022-01-12 コルテバ アグリサイエンス エルエルシー ピクロラムのハロゲン類似体の調製
CN111423434A (zh) * 2019-01-09 2020-07-17 四川海思科制药有限公司 一种碳酰胺衍生物及其制备方法
US20220380307A1 (en) * 2019-06-25 2022-12-01 Mylan Laboratories Limited Methods and intermediates for preparing hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide
CN116033893A (zh) 2020-06-26 2023-04-28 迈兰制药英国有限公司 包含5-[3-(3-羟基苯氧基)氮杂环丁烷-1-基]-5-甲基-2,2-二苯基己酰胺的制剂
WO2023049696A1 (en) * 2021-09-21 2023-03-30 Corteva Agriscience Llc Methylation of 2-chloro-6-fluorophenol

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2886574A (en) * 1956-11-19 1959-05-12 Upjohn Co Quaternary ammonium salts of 2, 2-diphenyl-4, 4-dimethyl-4-pyrrolidino-butyramide
US4219559A (en) * 1979-01-10 1980-08-26 Janssen Pharmaceutica N.V. N-Heterocyclyl-4-piperidinamines
GB8824262D0 (en) * 1988-10-17 1988-11-23 Pfizer Ltd Therapeutic agents
US5070087A (en) * 1989-05-08 1991-12-03 A. H. Robins Company, Incorporated Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl) aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory and antiallergy agents
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
CN1104239C (zh) * 1996-12-02 2003-04-02 杏林制药株式会社 新颖的n-取代的吡咯烷衍生物及其制备方法
EP0848964B1 (de) * 1996-12-17 2007-07-25 Filtertek B.V. Rückschlagventil, insbesondere für die Medizintechnik
JPH11100366A (ja) * 1997-09-29 1999-04-13 Kyorin Pharmaceut Co Ltd 新規n−置換環状アミン誘導体及びその製造法
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
WO2003053966A2 (en) 2001-12-20 2003-07-03 Laboratorios S.A.L.V.A.T., S.A. 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
EP1375508A1 (en) 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH N6-substituted adenosine analogues and their use as pharmaceutical agents
MXPA05002839A (es) 2002-09-17 2005-05-27 Actelion Pharmaceuticals Ltd Derivados de 1-piridin-4-il-urea.

Also Published As

Publication number Publication date
EP1928821B1 (en) 2009-01-07
AR055171A1 (es) 2007-08-08
CN101268046A (zh) 2008-09-17
ECSP088265A (es) 2008-04-28
RS51680B (en) 2011-10-31
AU2006293618B2 (en) 2009-10-08
MX2008002805A (es) 2008-04-07
KR20080037103A (ko) 2008-04-29
SI1928821T1 (sl) 2009-04-30
RS20080119A (en) 2009-05-06
HN2006032615A (es) 2010-10-04
NL2000241A1 (nl) 2007-03-22
US20100029720A1 (en) 2010-02-04
NZ566023A (en) 2010-02-26
GEP20104880B (en) 2010-01-11
WO2007034325A1 (en) 2007-03-29
BRPI0616111B8 (pt) 2021-05-25
CN101268046B (zh) 2012-07-25
JP4221447B1 (ja) 2009-02-12
CU23910B1 (nl) 2013-06-29
ATE420069T1 (de) 2009-01-15
TNSN08137A1 (fr) 2009-07-14
CR20130209A (es) 2013-09-19
UY29798A1 (es) 2007-04-30
CA2623332A1 (en) 2007-03-29
DE602006004768D1 (de) 2009-02-26
CR9814A (es) 2008-04-16
EP1928821A1 (en) 2008-06-11
NO20081001L (no) 2008-03-25
RS50855B (sr) 2010-08-31
ZA200801432B (en) 2009-07-29
HK1117163A1 (en) 2009-01-09
NL2000241C2 (nl) 2009-01-05
CU20100115A7 (es) 2011-10-14
DOP2006000202A (es) 2007-04-15
PL1928821T3 (pl) 2009-06-30
GT200600422A (es) 2007-05-28
AU2006293618B9 (en) 2009-10-29
AP1983A (en) 2009-03-24
KR100976909B1 (ko) 2010-08-18
PE20070460A1 (es) 2007-05-14
EA013083B1 (ru) 2010-02-26
MA29839B1 (fr) 2008-10-03
IL189453A (en) 2014-06-30
US8486992B2 (en) 2013-07-16
BRPI0616111B1 (pt) 2019-10-08
US20070105831A1 (en) 2007-05-10
TWI322143B (en) 2010-03-21
PT1928821E (pt) 2009-03-10
IL189453A0 (en) 2008-08-07
BRPI0616111A2 (pt) 2011-06-07
CA2623332C (en) 2012-05-01
TW200745024A (en) 2007-12-16
MY143581A (en) 2011-05-31
CY1108880T1 (el) 2014-07-02
DK1928821T3 (da) 2009-03-16
JP2009508933A (ja) 2009-03-05
ME01106B (me) 2013-03-20
US8268881B2 (en) 2012-09-18
EA200800540A1 (ru) 2008-08-29
US7772223B2 (en) 2010-08-10
NO340975B1 (no) 2017-07-31
AU2006293618A1 (en) 2007-03-29
ES2318794T3 (es) 2009-05-01
US20110251164A1 (en) 2011-10-13

Similar Documents

Publication Publication Date Title
HRP20090127T3 (en) Carboxamide derivatives as muscarinic receptor antagonists
MEP43308A (en) Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
PA8547901A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
ATE556058T1 (de) 1-(2h)-isochinolonderivat
PA8575401A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso
WO2008115098A3 (fr) 2,3,4,5-tétrahydro-1h-pyrido[4,3-b]indoles substitués ainsi que procédés de leur fabrication et leur utilisation
RS51007B (sr) Supstituisani piridinil i pirimidinil derivati kao modulatori metabolizma i lečenje poremećaja proisteklih iz toga
MEP10709A (en) 2-ARYL-6-PHENYLIMIDAZO[1,2-alpha]PYRIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
HRP20030943B1 (en) Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo 2,3-pyrimidine derivatives as protein kinases inhibitors
AR037682A1 (es) Derivados de acetileno que tienen actividad antagonista para receptores glutamato metabotropico humanos, composicion farmaceutica, una combinacion y el uso de dichos derivados para la fabricacion de composiciones farmaceuticas
ATE545647T1 (de) 5,6,7,8-tetrahydro-imidazoä1,5-aüpyrazinderivat
NI201000085A (es) Derivados bis - (sulfonilamino) en terapia 066.
NO20074071L (no) Hydrazinometyl, hydrozonometyl og 5-leddete heterocykliske forbindelser som virker som MTOR inhibitorer og anvendelse derav som anti-cancer midler
RS51574B (sr) JEDINJENJA PIROLO (2,3-d) PIRIMIDINA
EA200870362A1 (ru) Способ получения производных лактамида, новые производные лактамида и препараты, содержащие производные лактамида
UY30897A1 (es) Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones
WO2007144652A3 (en) Parp inhibitors
BR9809652A (pt) Derivados de quinolina-4-carboxamida como antagonistas de receptor nk-2 e nk-3
PL374019A1 (en) Benzoxazine derivatives as 5-ht6 modulators and uses thereof
RS54148B1 (en) PYRUVAMID COMPOUNDS AS INHIBITORS OF PEPTIDASE ALLERGEN GRINUS GROUP 1
AR054707A1 (es) Derivados de octahidropirrolo 3,4-c pirrol, un procedimiento para su preparacion, una composicion farmaceutica y uso del compuesto para la fabricacion de un medicamento
AR063059A1 (es) Derivados de quinolinona y 1,8-naftiridinona, composiciones farmaceuticas que los contienen y usos como agentes anti-vih.
HRP20080494T3 (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
BRPI0508404A (pt) derivado de (indol-3-il)-heterociclo, composição farmacêutica, uso de um derivado de (indol-3-il)-heterociclo, e método de tratamento da dor
HRP20030610B1 (en) Process for the preparation of mesylates of piperazine derivatives